The dementia-companion market is full of engagement statistics and empty of clinical constraint. We are taking the slower road: an eight-week feasibility study, CARE-SAT, with twenty caregiver–patient dyads, pre-specified endpoints, and a definition of failure written down before the first session runs. Satisfaction, caregiver burden, mood, sleep, and agitation are measured with standard instruments; safety events are defined, logged, and reported whether or not the results flatter us.
The ethical framework we build against is published independently by the Institute for AI Ethics in Human Cognition, whose oversight standard, and whose insistence that responsibility stays with humans, precedes and outranks this product.